MBX Biosciences reports $373.7M cash, expands obesity pipeline with two new candidates in 2026

MBX Biosciences, Inc.

Preliminary unaudited cash, cash equivalents and marketable securities of $373.7M at Dec 31, 2025; runway into 2029.
Canvuparatide (HP): 1-year follow-up data from Phase 2 in Q2 2026; Phase 3 start on track for Q3 2026.
MBX 4291 (obesity, GLP-1/GIP prodrug): 12-week Phase 1 data expected Q4 2026; potential once-monthly dosing.
Two additional obesity candidates to be nominated in Q2 and Q3 2026: amycretin prodrug and GLP-1/GIP/GCGR triple agonist.
Imapextide (PBH): Phase 2a data in Q2 2026; once-weekly dosing preferred in patient surveys.

item 2.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.